Scientist, Theranostics & Radiation Sciences

Scientist, Theranostics & Radiation Sciences

Join to apply for the Scientist, Theranostics & Radiation Sciences role at Astra Zeneca

Fusion Pharmaceuticals, a member of the AstraZeneca Group, is a clinical-stage oncology company focused on developing next-generation radio conjugates (RCs) as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha emitting payloads to tumors.

Fusion’s clinical portfolio includes but is not limited to: FPI-2265 targeting prostate specific membrane antigen (PSMA) for metastatic castration resistant prostate cancer currently in a Phase 2 trial; FPI-1434 targeting insulin-like growth factor 1 receptor currently in a Phase 1 trial; and FPI-2068, a bispecific IgG-based EGFR‑cMET targeted radio conjugate currently in a Phase 1 trial. Fusion has multiple other pipeline programs that will soon be entering into early FIH trials.

In addition, Fusion is pursuing combination programs between RCs and other therapeutic modalities including DNA Damage Response Inhibitors (DDRis) and immune‑oncology agents.

To support execution for these programs, Fusion has a fully operational Good Manufacturing Practice (GMP) compliant state‑of‑the‑art radio conjugate manufacturing facility to meet supply demand for our growing pipeline of RCs.

Candidates for the Imaging Scientist, Theranostics role need to work on a hybrid basis out of our Boston, Massachusetts office.

• Assist in the development of, and adherence to, imaging trial documents (e.g., Image Review Charter, Imaging Manual, Data Transmittal Forms, and Dosimetry Manuals).
• Provide subject matter expertise to internal and external stakeholders in matters of image acquisition, storage, review, and processing.
• Maintain an archive of imaging related data for ongoing and completed trials.
• Collaborate with clinical operations in the oversight, conduct and management of imaging‑related aspects of clinical studies in accordance with the clinical protocol, study manuals and plans, and timelines while ensuring quality in accordance with GCP and ICH guidelines.
• Assist with the management of in‑house processing of image data and internal dosimetry efforts to support ongoing research and multi‑disciplinary department and company initiatives.
• Provide support for clinical data review; assist in generation of clinical research reports and presentations including abstracts, posters, and publications.
• Provide support to clinical site staff and investigators pertaining to preparation, administration, and waste management of imaging and therapeutic radiopharmaceuticals.
• Respond to radiation safety questions and concerns regarding the use of diagnostic and therapeutic radiopharmaceuticals and precautions.
• Have a working knowledge and understanding of modern electronic infrastructures relevant to radiological imaging such as DICOM, PACS, IHE models, image processing and advanced visualization.
• Willingness to travel when needed (5‑10%).

• The candidate should have a Bachelor of Science degree with a life science focus from an accredited educational institution and NMTCB/ARRT(N) certification in nuclear medicine or equivalent. Additional training in radiation safety (NMTCB(RS)) and/or medical physics with an advanced master's qualifications is preferred but not required.
• Minimum of at least 5 years of clinical experience.
• Experience working in clinical trials for 2‑5 years is preferred but not required.
• Demonstrated technical and analytical problem‑solving skills.
• Scientific expertise in SPECT and PET imaging is recommended, including acquisition, reconstruction and uploading of images.
• Training in Good Clinical Practices (GCP), Quality Assurance/Compliance (QA/QC) in a clinical trial setting is preferred.
• Experience with radioactive materials license amendment process with the NRC and Agreement States.
• Familiar with Radiation Safety Officer (RSO) responsibilities.
• Ability to clearly articulate and present the role and impact of molecular imaging on decision making within drug discovery and development.
• Self‑motivation and exceptional verbal and written communication…